Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat Combined With Pyrotinib Plus Endocrine Therapy in Advanced Triple-Positive Breast Cancer
NCT07708194Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2025
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
A Phase 2 trial of entinostat in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jun 2025; status: recruiting.
02
Drugs
entinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07708194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708194.